These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23523344)

  • 21. Naturally occurring asbestos: a recurring public policy challenge.
    Lee RJ; Strohmeier BR; Bunker KL; Van Orden DR
    J Hazard Mater; 2008 May; 153(1-2):1-21. PubMed ID: 18180100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disinfectant drugs regulation.
    Perron N; Carman M
    Can J Infect Control; 1995; 10(4):117-8. PubMed ID: 8547684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health Canada's use of its priority review process for new drugs: a cohort study.
    Lexchin J
    BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-reported use of natural health products: a cross-sectional telephone survey in older Ontarians.
    Levine MA; Xu S; Gaebel K; Brazier N; Bédard M; Brazil K; Lohfeld L; MacLeod SM
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):383-92. PubMed ID: 20129259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The professionalization of Western herbalists: response to new product regulations in Canada.
    Moss K; Boon H; Ballantyne P; Kachan N
    Complement Ther Med; 2007 Dec; 15(4):264-70. PubMed ID: 18054728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dissection of differences and similarities of botanical drugs in European Union, US and Canada].
    He Y; Zhao L; Ye Z; Guo Z; Sun H
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(19):2747-50. PubMed ID: 22242441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A critical public-health ethics analysis of Canada's international response to HIV.
    Nixon SA; Benatar SR
    Glob Public Health; 2011; 6(7):777-93. PubMed ID: 21390963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
    Shaller D
    Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canadian regulatory requirements for recombinant fish vaccines.
    Sethi MS; Gifford GA; Samagh BS
    Dev Biol Stand; 1997; 90():347-53. PubMed ID: 9270863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Policy initiatives for health information technology: a qualitative study of U.S. expectations and Canada's experience.
    Salzberg CA; Jang Y; Rozenblum R; Zimlichman E; Tamblyn R; Bates DW
    Int J Med Inform; 2012 Oct; 81(10):713-22. PubMed ID: 22902272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
    Swain E; Morgan S; Brewster W; Kauser S
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
    Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A tale of three labels: translating the JUPITER trial data into regulatory claims.
    Ridker PM
    Clin Trials; 2011 Aug; 8(4):417-22. PubMed ID: 21835857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Community identification of natural health product-drug interactions.
    Charrois TL; Hill RL; Vu D; Foster BC; Boon HS; Cramer K; Vohra S
    Ann Pharmacother; 2007 Jul; 41(7):1124-9. PubMed ID: 17578882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A descriptive study evaluating Health Canada's risk communications.
    Bateman J; Charrois TL; Gardiner P; Vohra S
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1104-9. PubMed ID: 21692140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges to meat safety in the 21st century.
    Sofos JN
    Meat Sci; 2008 Jan; 78(1-2):3-13. PubMed ID: 22062090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meeting of minds: interdisciplinary research in the health sciences in Canada.
    Hall JG; Bainbridge L; Buchan A; Cribb A; Drummond J; Gyles C; Hicks TP; McWilliam C; Paterson B; Ratner PA; Skarakis-Doyle E; Solomon P
    CMAJ; 2006 Sep; 175(7):763-71. PubMed ID: 17001059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.